

# AGENDA & MEETING NOTICE

## Washington State Pharmacy and Therapeutics Committee

Date: October 18, 2006  
Time: 9:00 a.m. – 4:00 p.m.  
Location: Marriott Hotel  
3201 South 176<sup>th</sup> Street  
Seattle, WA 98188

9:00 a.m. – 9:05 a.m.	Welcome & Introductions	Dan Lessler, M.D. P&T Committee Chair
9:05 a.m. – 10:00 a.m.	Drug Class Review – <b>Update</b> <b>Statins</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <b>TBD</b> <i>Stakeholders</i> P & T Committee
10:00 a.m. – 10:15 a.m.	Break	All
10:15 a.m. – 11:15 a.m.	Drug Class Review – <b>Update</b> <b>Anti Platelets – CANCELLED REPORT NOT AVAILABLE</b>	Break
11:15 a.m. – 12:00 p.m.	Drug Class Review – <b>Update</b> <b>Drugs to treat Alzheimer's</b> <i>Stakeholder comments: Limit 3 minutes per person</i> P & T Committee discussion and motions	OHSU EPC Staff <b>Rick Hansen</b> <i>Stakeholders</i> P & T Committee
12:00 p.m. – 1:00 p.m.	Lunch – <i>On your own</i>	All
1:00 p.m. – 4:00 p.m.	<b>Drug Utilization Review (DUR) for Washington</b>  <b>A: Medicaid FFY 2006 DUR Activity</b>  1) <u>Background:</u> HRSA is required by federal regulation to conduct retrospective and prospective DUR each year to monitor the appropriateness of drug therapy for Medicaid Clients.  2) <u>Today's Presentation:</u> ACS clinical pharmacists will present the DUR activity conducted in FFY 2006 for Washington Medicaid.  3) <u>Expected Outcome:</u> DUR Board members will be able to use the information to assist them when writing the FFY 2006 Annual DUR Report due to CMS, Region X, June 30, 2007.	Ileana Soto, Pharm D, Affiliated Computer Services (ACS) Krista Issackson, RPh, ACS

## AGENDA & MEETING NOTICE

### **B: Secondary Sign-Off process for Mental Health Drugs**

- 1) Background: HRSA has implemented a second review process for the ADHD age and dose limits and will be working with the Mental Health Drug Workgroup to develop a secondary sign-off process for other mental health drug initiatives such as polypharmacy.
- 2) Today's Presentation: Dr. Thompson will discuss the progress made to date on the secondary sign-off process.
- 3) Expected Outcome: DUR Board approval of HRSA's secondary sign-off process.

Jeff Thompson, MD  
Chief Medical  
Officer/ Director  
DMM  
Health and Recovery  
Services  
Administration  
Dept of Social and  
Health Services

### **C: Education and Communication on Polypharmacy. Polypharmacy and combination use of AAPs Mental Health**

- 1) Background: HRSA will be communicating the Mental Health Work Group recommendations on Polypharmacy, polypharmacy and combination use of AAPs.
- 2) Today's Presentation: Dr. Thompson will discuss the progress made to date on these best practices and EBM approach to be communicated.
- 3) Expected Outcome: DUR Board approval of HRSA's education and communication plan.

Jeff Thompson, MD  
Chief Medical  
Officer/ Director  
DMM  
Health and Recovery  
Services  
Administration  
Dept of Social and  
Health Services

4:00 p.m.

Adjourn

### **Additional Information**

#### **Special notes:**

If you are a person with a disability and need a reasonable accommodation or have questions, please call Regina Chacón at (206) 521-2027.